All In Biotech

Drug Trial Radar · NCT07220460

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Actual

Start

Sep 30, 2025

Primary completion

Mar 2027

Study completion Apr 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Bipolar I or II Disorder

Interventions

  • ABBV-932Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 29 weeks
  2. Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to week 26
  3. Number of Participants with Change from Baseline in Electrocardiogram (ECG)Time frame: Up to week 26
  4. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to week 26
  5. Change From Baseline in Simpson-Angus Scale (SAS)Time frame: Up to week 26
  6. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Up to week 26
  7. Change From Baseline in Barnes Akathisia Rating Scale (BARS)Time frame: Up to week 26
  8. Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to week 26
  9. Change From Baseline in the Epworth Sleepiness Scale (ESS)Time frame: Up to week 26
  10. Change From Baseline in the Young Mania Rating Scale (YMRS)Time frame: Up to week 26
  11. Number of Participants with Abnormal Change in Ocular ExaminationTime frame: Up to week 26

Locations

49 sites in 2 countries. Site status is shown where the registry gives one.

  • Ima Clinical Research Phoenix /ID# 278047

    Phoenix, Arizona

  • Advanced Research Center /ID# 273474

    Anaheim, California

  • Axiom Research /ID# 273482

    Colton, California

  • Collaborative Neuroscience Research - Garden Grove /ID# 273492

    Garden Grove, California

  • Sun Valley Research Center /ID# 273472

    Imperial, California

  • Synergy San Diego /ID# 278340

    Lemon Grove, California

  • Alliance for Research Alliance for Wellness /ID# 273477

    Long Beach, California

  • Nrc Research Institute - Los Angeles /ID# 278450

    Los Angeles, California

  • Excell Research /ID# 273483

    Oceanside, California

  • Inland Psychiatric Medical Group /ID# 273471

    Temecula, California

  • Sunwise Clinical Research /ID# 278165

    Walnut Creek, California

  • Connecticut Clinical Research - Cromwell /ID# 278116

    Cromwell, Connecticut

  • Clinical Neuroscience Solutions Healthcare - Jacksonville /ID# 278332

    Jacksonville, Florida

  • Segal Trials - Lauderhill /ID# 273496

    Lauderhill, Florida

  • K2 Medical Research -Maitland /ID# 273487

    Maitland, Florida

  • GMI Florida - Central Miami Medical Institute (SMO/Network/Consortium) /ID# 273486

    Miami, Florida

  • Allied Biomedical Res Inst Inc /ID# 273476

    Miami, Florida

  • Floridian Clinical Research - Miami Lakes /ID# 279379

    Miami Lakes, Florida

  • Apg Research /ID# 278439

    Orlando, Florida

  • Health Synergy Clinical Research - West Palm Beach /ID# 279384

    West Palm Beach, Florida

  • Trialmed /ID# 278046

    Atlanta, Georgia

  • Atlanta Center for Medical Research /ID# 278827

    Atlanta, Georgia

  • Revive Research Institute - Elgin /ID# 279756

    Elgin, Illinois

  • Benchmark Research /ID# 273490

    Shreveport, Louisiana

  • Pharmasite Research, Inc. /ID# 279163

    Baltimore, Maryland

  • Voltaire - Springfield /ID# 278446

    Springfield, Massachusetts

  • MSB Neuroscience /ID# 278168

    Jackson, Mississippi

  • Arch Clinical Trials /ID# 273481

    St Louis, Missouri

  • Alivation Research - Lincoln /ID# 279464

    Lincoln, Nebraska

  • Ima Clinical Research Las Vegas /ID# 278054

    Las Vegas, Nevada

  • Redbird Research /ID# 279475

    Las Vegas, Nevada

  • Bio Behavioral Health /ID# 273478

    Toms River, New Jersey

  • Integrative Clinical Trials /ID# 278040

    Brooklyn, New York

  • Neurobehavioral Research /ID# 273470

    Cedarhurst, New York

  • Ima Clinical Research - Manhattan /ID# 278941

    New York, New York

  • New Hope Clinical Research /ID# 273468

    Charlotte, North Carolina

  • Quest Therapeutics of Avon Lake /ID# 273484

    Avon Lake, Ohio

  • OSU Psychiatry Department /ID# 273495

    Columbus, Ohio

  • Sooner Clinical Research /ID# 273491

    Oklahoma City, Oklahoma

  • Summit Research Network - Portland - Northwest Vaughn Street /ID# 278084

    Portland, Oregon

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.